Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) will be presenting at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 10, 2021, at 11:40 a.m. Pacific Time. Bill Lis, Executive Chairman and CEO, will lead the presentation, which will be available via a live webcast. Jasper focuses on hematopoietic cell transplant therapies, with two promising programs in development: JSP191, a monoclonal antibody aimed at safer transplants, and a preclinical mRNA engineered hematopoietic stem cell platform. Their innovations aim to expand treatment options for patients with serious medical conditions.